Lv51
930 积分 2024-09-01 加入
Reprogramming site-specific retrotransposon activity to new DNA sites
4小时前
待确认
Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery
10天前
已完结
Engineering sonogenetic EchoBack-CAR T cells
11天前
已完结
BCMA-CAR T-cells in a patient with relapsing idiopathic inflammatory myositis after CD19-CAR T-cells
15天前
已完结
Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis
26天前
已完结
Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy
26天前
已完结
Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies
26天前
已完结
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
26天前
已完结
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
29天前
已完结
Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR‐T) Cell Therapy Targeting Delta‐Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
1个月前
已完结
皖公网安备34019202002308
